IN2012DN03807A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03807A
IN2012DN03807A IN3807DEN2012A IN2012DN03807A IN 2012DN03807 A IN2012DN03807 A IN 2012DN03807A IN 3807DEN2012 A IN3807DEN2012 A IN 3807DEN2012A IN 2012DN03807 A IN2012DN03807 A IN 2012DN03807A
Authority
IN
India
Prior art keywords
methods
cognitive function
dinaline
impairments
metabolite
Prior art date
Application number
Other languages
English (en)
Inventor
Li-Huei Tsai
Ji-Song Guan
Stephen J Haggarty
Edward Holson
Florence Wagner
Johannes Graeff
Original Assignee
Massachusetts Inst Technology
Gen Hospital Corp
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Gen Hospital Corp, Broad Inst Inc filed Critical Massachusetts Inst Technology
Publication of IN2012DN03807A publication Critical patent/IN2012DN03807A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3807DEN2012 2009-10-30 2010-10-29 IN2012DN03807A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25692709P 2009-10-30 2009-10-30
US26546809P 2009-12-01 2009-12-01
PCT/US2010/054872 WO2011053876A1 (fr) 2009-10-30 2010-10-29 Utilisation de ci-994 et de dinaline pour le traitement de troubles de la mémoire/cognition et de l'anxiété

Publications (1)

Publication Number Publication Date
IN2012DN03807A true IN2012DN03807A (fr) 2015-08-28

Family

ID=43922604

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3807DEN2012 IN2012DN03807A (fr) 2009-10-30 2010-10-29

Country Status (9)

Country Link
US (2) US8563615B2 (fr)
EP (1) EP2493298A4 (fr)
JP (1) JP2013509441A (fr)
CN (1) CN102834002A (fr)
AU (1) AU2010313255B2 (fr)
CA (1) CA2779497A1 (fr)
IN (1) IN2012DN03807A (fr)
NZ (1) NZ599757A (fr)
WO (1) WO2011053876A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US8263547B2 (en) * 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
EP2493298A4 (fr) 2009-10-30 2013-04-10 Massachusetts Inst Technology Utilisation de ci-994 et de dinaline pour le traitement de troubles de la mémoire/cognition et de l'anxiété
WO2012003413A1 (fr) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Nouvelles formes solides de tacédinaline
JP6240063B2 (ja) 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
DK2734510T3 (en) 2011-07-22 2019-03-04 Massachusetts Inst Technology CLASS I-HISTONDEACETYLASES (HDAC) ACTIVATORS AND APPLICATIONS THEREOF
WO2014018979A1 (fr) * 2012-07-27 2014-01-30 The Broad Institute, Inc. Inhibiteurs d'histone-désacétylases
WO2014046871A1 (fr) * 2012-09-04 2014-03-27 Massachusetts Institute Of Technology Utilisation d'un profilage d'expression génétique comme biomarqueur pour évaluer l'efficacité d'un traitement de maladies neurodégénératives par un inhibiteur de hdac
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
CN112062826A (zh) * 2020-06-01 2020-12-11 暨南大学 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用
WO2023034440A1 (fr) * 2021-09-01 2023-03-09 Case Western Reserve University Traitement de maladies neurodégénératives avec des inhibiteurs de hdac

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
EP1212357B1 (fr) 1999-09-08 2007-05-02 Sloan-Kettering Institute For Cancer Research Structure cristalline d'une deacetylase et ses inhibiteurs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CA2391952C (fr) 1999-11-23 2012-01-31 Methylgene Inc. Inhibiteurs de l'histone deacetylase
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
WO2002030879A2 (fr) * 2000-09-29 2002-04-18 Prolifix Limited Composes d'acide carbamique comprenant une liaison sulfonamide en tant qu'inhibiteurs de hdac
US20060148743A1 (en) 2001-05-18 2006-07-06 Vasant Jadhav RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
CA2450129A1 (fr) 2001-06-14 2002-12-27 Donald G. Jackson Nouvelles histones deacetylases humaines
EP1429765A2 (fr) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibiteurs de l'histone-deacetylase
EP1443928B1 (fr) * 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Traitement des maladies neurodegeneratives et du cancer du cerveau
EP1456664A1 (fr) 2001-12-07 2004-09-15 Novartis AG Utilisation des niveaux d'acetylation d'alpha-tubuline en tant que biomarqueur d'inhibiteurs de deacetylase proteique
WO2003066889A2 (fr) 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Dosage permettant de mesurer l'activite d'acetylation ou de deacetylation d'une enzyme
AU2003214055A1 (en) 2002-02-08 2003-09-02 Novartis Ag Method for screening for compounds having hdac inhibitory activity
US20050288227A1 (en) 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
US20030224473A1 (en) 2002-05-23 2003-12-04 Mccafferty Dewey G. Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
EP1551795A1 (fr) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibiteurs de l'histone deacetylase
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
EP1663953A1 (fr) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
WO2005048942A2 (fr) * 2003-11-13 2005-06-02 Pharmacia Corporation Polytherapie contenant un inhibiteur cox-2 et un agent antineoplasique
WO2005092899A1 (fr) 2004-03-26 2005-10-06 Methylgene Inc. Inhibiteurs d'histone désacétylase
CA2563617A1 (fr) * 2004-04-20 2005-11-03 Rnd Pharmaceuticals Compositions pharmaceutiques et methodes d'utilisation de medicaments et de derives de cyclo-oxygenase-2 lipophiles a substitution silicium
DK1591109T3 (da) * 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
US20060160902A1 (en) 2004-11-08 2006-07-20 Wiech Norbert L Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20070015183A1 (en) 2005-06-03 2007-01-18 The General Hospital Corporation Biomarkers for huntington's disease
CA2615105A1 (fr) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Inhibiteurs de l'histone deacetylase
JP2009507081A (ja) 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド ＨＤａｃ阻害による神経発生の調整
WO2007049262A1 (fr) * 2005-10-27 2007-05-03 Berand Limited Procedes et compositions pour favoriser la croissance neuronale et le traitement de l'asociabilite et des troubles affectifs
WO2007055942A2 (fr) 2005-11-03 2007-05-18 Merck & Co., Inc. Composes de nicotinamide substitue
US7670817B2 (en) * 2005-11-08 2010-03-02 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
AU2007221207A1 (en) 2006-02-28 2007-09-07 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
JP5554988B2 (ja) 2006-04-07 2014-07-23 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
EP2013196B1 (fr) 2006-04-26 2015-09-16 Merck Sharp & Dohme Corp. Composés de l'aniline disubstitués
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
US20100112600A1 (en) 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US8263547B2 (en) * 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
US20100075926A1 (en) * 2008-07-23 2010-03-25 Li-Huei Tsai Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
JP2012510512A (ja) * 2008-12-03 2012-05-10 マサチューセッツ インスティテュート オブ テクノロジー 記憶を推進するためのｈｄａｃ２の阻害
WO2010098888A1 (fr) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Utilisations de produits chimiques pour moduler la signalisation par gsk–3 pour le traitement d'un trouble bipolaire et autres troubles cérébraux
EP2493298A4 (fr) * 2009-10-30 2013-04-10 Massachusetts Inst Technology Utilisation de ci-994 et de dinaline pour le traitement de troubles de la mémoire/cognition et de l'anxiété
DK2734510T3 (en) * 2011-07-22 2019-03-04 Massachusetts Inst Technology CLASS I-HISTONDEACETYLASES (HDAC) ACTIVATORS AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
EP2493298A4 (fr) 2013-04-10
WO2011053876A1 (fr) 2011-05-05
NZ599757A (en) 2014-08-29
AU2010313255B2 (en) 2015-04-30
CA2779497A1 (fr) 2011-05-05
US8841346B2 (en) 2014-09-23
JP2013509441A (ja) 2013-03-14
CN102834002A (zh) 2012-12-19
US8563615B2 (en) 2013-10-22
AU2010313255A1 (en) 2012-05-31
US20120322879A1 (en) 2012-12-20
EP2493298A1 (fr) 2012-09-05
US20110224303A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
IN2012DN03807A (fr)
JOP20180102B1 (ar) مركب صيدلاني
IN2014CN02616A (fr)
MX2011007930A (es) Conjugados de insulina cristalina.
WO2013072932A3 (fr) Compositions de soin oral
HK1220631A1 (zh) 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法
AP2012006189A0 (en) 2'-fluoro substituted carbanucleoside analogs for antiviral treatment.
MX356210B (es) Formulaciones de polimero acrilico.
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
WO2011057262A3 (fr) Traitement des infections par des antagonistes du récepteur tp
EP2130909A4 (fr) Procédé de production de dent et dent produite par le procédé
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
TW200942530A (en) Pyridine compounds
MY155330A (en) Methods for salt production
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
GB2482817A (en) Novel use
EP2794806A4 (fr) Compositions de type azéotropique comprenant du cis-1-chloro-3,3,3-trifluoropropène
EP2576575A4 (fr) Composés conjugués prostaglandine-bisphosphonate, leurs méthodes de fabrication et leurs utilisations
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2009011901A3 (fr) Procédés pour favoriser la veille
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
WO2012082942A3 (fr) Analogues de neuropeptides, compositions et procédés pour le traitement de la douleur